Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMV Inc. to Present at Two Upcoming Investor Conferences

IMVIF

IMV Inc. to Present at Two Upcoming Investor Conferences

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019.

Details on each conference and presentation are as follows:

 

Venue: Spring Investor Summit, being held April 1-2, 2019

Date of Presentation: Monday, April 1

Time: 8:30 a.m. ET

Location: JW Marriott Hotel, Essex House, New York City

 

Venue: HC Wainwright Global Life Sciences Conference, being held April 7-9, 2019

Date: Tuesday, April 9, 2019

Time: 10:40 a.m. BST

Location: Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK

 

There will be a live webcast of both of these presentations available in the events, presentations and webcasts section of IMV’s website. Following the presentations, the webcasts will be archived for 90 days and a copy of the presentations will remain available in the same section of the website.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

Investor Relations:
Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819 ext : 1042
M: (514) 617-9481
E: mjasmin@imv-inc.com

Media:
Andrea Cohen, Sam Brown Inc.
T: (917) 209-7163
E: andreacohen@sambrown.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today